ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.405,92
-0,11%
S&P 500
6.051,09
0,00%
Dow Jones
43.828,06
-0,20%
Euro vs US Dollar
1,0502
0,00%
Bitcoin
104.870,92
3,40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Alligator Bioscience Ab (0RK9)

  7. Alligator Bioscience Ab (0RK9) News

0RK9

Alligator Bioscience Ab (0RK9)

Alligator Bioscience Ab
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0RK9
DatumZeitQuelleÜberschriftSymbolFirma
01/04/202208h20PR Newswire (US)Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort CommencesLSE:0RK9Alligator Bioscience Ab
01/04/202208h19PR Newswire (US)Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort CommencesLSE:0RK9Alligator Bioscience Ab
23/03/202209h07PR Newswire (US)Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kgLSE:0RK9Alligator Bioscience Ab
23/03/202209h06PR Newswire (US)Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kgLSE:0RK9Alligator Bioscience Ab
11/02/202208h23PR Newswire (US)Alligator Bioscience AB: Year End report January-December 2021LSE:0RK9Alligator Bioscience Ab
11/02/202208h22PR Newswire (US)Alligator Bioscience AB: Year End report January-December 2021LSE:0RK9Alligator Bioscience Ab
01/02/202209h16PR Newswire (US)Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical OfficerLSE:0RK9Alligator Bioscience Ab
01/02/202208h20PR Newswire (US)Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical OfficerLSE:0RK9Alligator Bioscience Ab
19/01/202208h42PR Newswire (US)Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory BeattyLSE:0RK9Alligator Bioscience Ab
19/01/202208h41PR Newswire (US)Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory BeattyLSE:0RK9Alligator Bioscience Ab
18/01/202208h19PR Newswire (US)Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects ReportedLSE:0RK9Alligator Bioscience Ab
18/01/202208h16PR Newswire (US)Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects ReportedLSE:0RK9Alligator Bioscience Ab
16/12/202108h41PR Newswire (US)Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability DataLSE:0RK9Alligator Bioscience Ab
16/12/202108h39PR Newswire (US)Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability DataLSE:0RK9Alligator Bioscience Ab
15/12/202114h37PR Newswire (US)Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationLSE:0RK9Alligator Bioscience Ab
15/12/202114h36PR Newswire (US)Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationLSE:0RK9Alligator Bioscience Ab
08/11/202117h54PR Newswire (US)Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University RotterdamLSE:0RK9Alligator Bioscience Ab
08/11/202117h53PR Newswire (US)Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University RotterdamLSE:0RK9Alligator Bioscience Ab
08/11/202116h59PR Newswire (US)Bulletin from the extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
08/11/202116h57PR Newswire (US)Bulletin from the extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
21/10/202108h45PR Newswire (US)Alligator Bioscience AB: Interim report January-September 2021LSE:0RK9Alligator Bioscience Ab
21/10/202108h41PR Newswire (US)Alligator Bioscience AB: Interim report January-September 2021LSE:0RK9Alligator Bioscience Ab
07/10/202108h25PR Newswire (US)Notice of extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
07/10/202108h23PR Newswire (US)Notice of extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
02/09/202112h17PR Newswire (US)Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipelineLSE:0RK9Alligator Bioscience Ab
02/09/202112h14PR Newswire (US)Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipelineLSE:0RK9Alligator Bioscience Ab
02/09/202110h33PR Newswire (US)Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination TherapyLSE:0RK9Alligator Bioscience Ab
18/08/202108h50PR Newswire (US)Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion CorporationLSE:0RK9Alligator Bioscience Ab
18/08/202108h49PR Newswire (US)Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion CorporationLSE:0RK9Alligator Bioscience Ab
16/08/202115h16PR Newswire (US)Alligator Bioscience Announces New Senior Director of Communications & Investor RelationsLSE:0RK9Alligator Bioscience Ab
 Showing the most relevant articles for your search:LSE:0RK9

Kürzlich von Ihnen besucht

COIN
AVAXUSD
Avalanche
FX
EURUSD
Euro vs US Dollar
NASDAQ
GOOGL
Alphabet
AMEX
XLV
Health Care Select Sector
TG
MBG
MercedesBenz
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
COIN
XRPUSD
Ripple
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
TG
BAYN
Bayer
AMEX
XLE
Energy Select Sector SPDR
DBI
DAX
DAX
DBI
TDXP
Tec DAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten